학술논문
Biokinetics and dosimetry in patients administered with [sup 111] In-DOTA-Tyr[sup 3] -octreotide: implications for internal radiotherapy with [sup 90] Y-DOTATOC.
Document Type
Article
Author
Source
Subject
*TUMORS
*SOMATOSTATIN
*DRUG dosage
*POSITRON emission tomography
*
*
*
Language
ISSN
0340-6997
Abstract
Abstract. Recent advances in receptor-mediated tumour imaging have resulted in the development of a new somatostatin analogue, DOTA-DPhe[sup 1]-Tyr[sup 3]-octreotide. This new compound, named DOTATOC, has shown high affinity for somatostatin receptors, ease of labelling and stability with yttrium-90 and favourable biodistribution in animal models. The aim of this work was to evaluate the biodistribution and dosimetry of DOTATOC radiolabelled with indium-111, in anticipation of therapy trials with [sup 90]Y-DOTATOC in patients. Eighteen patients were injected with DOTATOC (10 micro g), labelled with 150-185 MBq of [sup 111]In. Blood and urine samples were collected throughout the duration of the study (0-2 days). Planar and single-photon emission tomography images were acquired at 0.5, 3-4, 24 and 48 h and time-activity curves were obtained for organs and tumours. A compartmental model was used to determine the kinetic parameters for each organ. Dose calculations were performed according to the MIRD formalism. Specific activities of >37 GBq/ mu mol were routinely achieved. Patients showed no acute or delayed adverse... [ABSTRACT FROM AUTHOR]